UA108878C2 - Ингибиторы протеинтирозинкиназной активности - Google Patents

Ингибиторы протеинтирозинкиназной активности

Info

Publication number
UA108878C2
UA108878C2 UAA201211687A UAA201211687A UA108878C2 UA 108878 C2 UA108878 C2 UA 108878C2 UA A201211687 A UAA201211687 A UA A201211687A UA A201211687 A UAA201211687 A UA A201211687A UA 108878 C2 UA108878 C2 UA 108878C2
Authority
UA
Ukraine
Prior art keywords
tyrosine kinase
compounds
xii
formulae
viii
Prior art date
Application number
UAA201211687A
Other languages
English (en)
Ukrainian (uk)
Inventor
Стефан Раппель
Ліджі Жан
Стівен Уільям Кларідж
Франк РАППЕЛЬ
Фредерік Годетт
Аркадій Вайсбург
Original Assignee
Метилджен Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Метилджен Інк. filed Critical Метилджен Інк.
Publication of UA108878C2 publication Critical patent/UA108878C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Настоящее изобретение касается новых соединений и их композиций. Изобретение также касается способа лечения офтальмологических заболеваний, расстройств и болезненных состояний.
UAA201211687A 2010-04-16 2011-04-08 Ингибиторы протеинтирозинкиназной активности UA108878C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32480310P 2010-04-16 2010-04-16
PCT/CA2011/000390 WO2011127565A1 (en) 2010-04-16 2011-04-08 Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders

Publications (1)

Publication Number Publication Date
UA108878C2 true UA108878C2 (ru) 2015-06-25

Family

ID=44788641

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201211687A UA108878C2 (ru) 2010-04-16 2011-04-08 Ингибиторы протеинтирозинкиназной активности

Country Status (18)

Country Link
US (3) US8906852B2 (ru)
EP (2) EP2563794A4 (ru)
JP (2) JP2013525286A (ru)
KR (2) KR20130058006A (ru)
CN (2) CN102947315A (ru)
AR (2) AR080875A1 (ru)
AU (2) AU2011241422B2 (ru)
CA (2) CA2796054A1 (ru)
CO (2) CO6640224A2 (ru)
EA (2) EA201291055A1 (ru)
MX (2) MX2012012032A (ru)
MY (1) MY157319A (ru)
NZ (2) NZ602954A (ru)
SG (2) SG184883A1 (ru)
TW (2) TW201204734A (ru)
UA (1) UA108878C2 (ru)
WO (2) WO2011127567A1 (ru)
ZA (2) ZA201207482B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2495044C2 (ru) * 2007-08-29 2013-10-10 Метилджен Инк. Ингибиторы активности протеинтирозинкиназы
CN102161663B (zh) * 2008-03-05 2014-03-19 梅特希尔基因公司 蛋白酪氨酸激酶活性的抑制剂
EP2563794A4 (en) * 2010-04-16 2013-12-04 Methylgene Inc INHIBITORS OF TYROSINE KINASE PROTEIN ACTIVITY AND THEIR APPLICATIONS TO THE TREATMENT OF OPHTHALMIC DISORDERS
WO2013044362A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Selected inhibitors of protein tyrosine kinase activity
US20130096088A1 (en) * 2011-09-30 2013-04-18 Methylgene Inc. Inhibitors of Protein Tyrosine Kinase Activity
WO2013044360A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
CA2857603C (en) 2011-12-15 2016-08-02 Pfizer Limited Sulfonamide derivatives
US10544117B2 (en) 2014-09-10 2020-01-28 Temple University—Of the Commonwealth System of Higher Education 5-hydroxytryptamine receptor 7 activity modulators and their method of use
US20180221365A1 (en) * 2015-05-12 2018-08-09 Temple University-Of The Commonwealth System Of Higher Education Novel sigma-2 receptor binders and their method of use
CN108530464B (zh) * 2017-03-02 2020-10-27 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050020619A1 (en) * 2003-07-24 2005-01-27 Patrick Betschmann Thienopyridine kinase inhibitors
AU2005266803B2 (en) * 2004-07-30 2011-10-27 Methylgene Inc. Inhibitors of VEGF receptor and HGF receptor signaling
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
NZ564283A (en) * 2005-05-20 2011-07-29 Methylgene Inc Inhibitors of VEGF receptor and HGF receptor signaling
US7790729B2 (en) * 2005-05-20 2010-09-07 Methylgene Inc. Inhibitors of VEGF receptor and HGF receptor signaling
US8907091B2 (en) * 2007-08-29 2014-12-09 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
RU2495044C2 (ru) * 2007-08-29 2013-10-10 Метилджен Инк. Ингибиторы активности протеинтирозинкиназы
CN102161663B (zh) * 2008-03-05 2014-03-19 梅特希尔基因公司 蛋白酪氨酸激酶活性的抑制剂
EP2563794A4 (en) * 2010-04-16 2013-12-04 Methylgene Inc INHIBITORS OF TYROSINE KINASE PROTEIN ACTIVITY AND THEIR APPLICATIONS TO THE TREATMENT OF OPHTHALMIC DISORDERS
US20130096088A1 (en) * 2011-09-30 2013-04-18 Methylgene Inc. Inhibitors of Protein Tyrosine Kinase Activity

Also Published As

Publication number Publication date
US8455484B2 (en) 2013-06-04
TW201204735A (en) 2012-02-01
AR080875A1 (es) 2012-05-16
EA201291055A1 (ru) 2013-09-30
EP2563794A4 (en) 2013-12-04
JP2013523846A (ja) 2013-06-17
CN103025740A (zh) 2013-04-03
EA201291052A1 (ru) 2013-04-30
EP2563794A1 (en) 2013-03-06
CN102947315A (zh) 2013-02-27
MX2012012032A (es) 2012-12-17
NZ602954A (en) 2014-11-28
NZ602948A (en) 2014-09-26
WO2011127567A1 (en) 2011-10-20
SG184882A1 (en) 2012-11-29
JP2013525286A (ja) 2013-06-20
KR20130058006A (ko) 2013-06-03
CA2796008A1 (en) 2011-10-20
US20110257100A1 (en) 2011-10-20
WO2011127565A1 (en) 2011-10-20
EP2563795A4 (en) 2013-10-23
AR080871A1 (es) 2012-05-16
AU2011241422B2 (en) 2015-05-07
US20110257175A1 (en) 2011-10-20
CN103025740B (zh) 2015-07-01
CO6640224A2 (es) 2013-03-22
AU2011241420B2 (en) 2015-04-16
KR20130100234A (ko) 2013-09-10
AU2011241422A1 (en) 2012-11-01
US20140315801A1 (en) 2014-10-23
TW201204734A (en) 2012-02-01
ZA201207557B (en) 2013-06-26
CA2796054A1 (en) 2011-10-20
MY157319A (en) 2016-05-31
MX2012012031A (es) 2012-12-17
ZA201207482B (en) 2013-09-25
EP2563795A1 (en) 2013-03-06
US8906852B2 (en) 2014-12-09
SG184883A1 (en) 2012-11-29
CO6630193A2 (es) 2013-03-01

Similar Documents

Publication Publication Date Title
UA108878C2 (ru) Ингибиторы протеинтирозинкиназной активности
AU2018236800B2 (en) DNA-PK inhibitors
PH12015502575B1 (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors
EA024842B9 (ru) Соединения в качестве модуляторов протеинкиназы pi3k
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
TN2012000081A1 (en) Compounds and compositions as protein kinase inhibitors
MX339937B (es) Compuestos y composiciones como inhibidores de la quinasa c-kit.
MX342329B (es) Compuestos y composiciones como inhibidores de la quinasa c-kit.
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
EA200901486A1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ, КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR
MX2015002044A (es) Pirazolil-ureas como inhibidores de quinasa.
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
IN2014KN02601A (ru)
IL200793A0 (en) Aminopyrimidines, compositions comprising the same and use thereof for inhibiting protein kinases
JO3366B1 (ar) مثبطات بيرازوليل كوينوكزالين كاينيز
AU2012253759A8 (en) Tricyclic sulfonamide compounds and methods of making and using same
MA32393B1 (fr) Composés et compositions servant d'inhibiteurs de kinases
MX2014002486A (es) Compuestos y composiciones como inhibidores de cinasa pdgfr.
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
MX2009010127A (es) Compuestos utiles como inhibidores de janus cinasas.
EA200901484A1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR
ATE502935T1 (de) C-met-proteinkinasehemmer
MX2011012524A (es) Inhibidores de proteina cinasa c-met.
MY198316A (en) Piperidin-4-YL Azetidine Derivatives as JAK1 Inhibitors
UA110978C2 (uk) Азетидинілфенілові, піридилові або піразинілкарбоксамідні похідні як інгібітори jak